Integrated Quantitative Investments LLC Purchases Shares of 39,147 Pacira BioSciences, Inc. (NASDAQ:PCRX)

Integrated Quantitative Investments LLC bought a new stake in Pacira BioSciences, Inc. (NASDAQ:PCRX - Free Report) in the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor bought 39,147 shares of the company's stock, valued at approximately $738,000. Integrated Quantitative Investments LLC owned approximately 0.08% of Pacira BioSciences as of its most recent filing with the Securities and Exchange Commission (SEC).

Other hedge funds and other institutional investors also recently made changes to their positions in the company. Verition Fund Management LLC acquired a new stake in Pacira BioSciences during the 3rd quarter worth $493,000. Centiva Capital LP bought a new position in shares of Pacira BioSciences during the 3rd quarter valued at about $398,000. State Street Corp grew its position in shares of Pacira BioSciences by 5.8% in the 3rd quarter. State Street Corp now owns 2,014,012 shares of the company's stock valued at $30,311,000 after purchasing an additional 110,162 shares during the period. Nisa Investment Advisors LLC raised its holdings in Pacira BioSciences by 495.3% during the 4th quarter. Nisa Investment Advisors LLC now owns 3,304 shares of the company's stock worth $62,000 after buying an additional 2,749 shares during the period. Finally, Charles Schwab Investment Management Inc. lifted its stake in Pacira BioSciences by 16.3% in the fourth quarter. Charles Schwab Investment Management Inc. now owns 502,204 shares of the company's stock valued at $9,462,000 after buying an additional 70,307 shares in the last quarter. 99.73% of the stock is owned by institutional investors.

Wall Street Analysts Forecast Growth

PCRX has been the topic of a number of research analyst reports. HC Wainwright raised their price objective on shares of Pacira BioSciences from $48.00 to $65.00 and gave the stock a "buy" rating in a report on Tuesday. Truist Financial raised Pacira BioSciences from a "sell" rating to a "hold" rating and upped their price objective for the stock from $8.00 to $25.00 in a research report on Thursday, January 30th. Royal Bank of Canada reissued a "sector perform" rating and issued a $18.00 target price on shares of Pacira BioSciences in a research report on Tuesday, January 14th. Needham & Company LLC reaffirmed a "buy" rating and set a $32.00 price target on shares of Pacira BioSciences in a research report on Tuesday. Finally, Barclays raised their price target on shares of Pacira BioSciences from $17.00 to $24.00 and gave the stock an "overweight" rating in a research note on Friday, February 28th. One investment analyst has rated the stock with a sell rating, four have assigned a hold rating and five have assigned a buy rating to the company's stock. According to MarketBeat, the company presently has an average rating of "Hold" and a consensus target price of $26.67.

Pacira BioSciences Stock Performance

Shares of PCRX traded down $2.43 during midday trading on Thursday, reaching $23.41. The stock had a trading volume of 668,253 shares, compared to its average volume of 963,701. The firm has a market cap of $1.08 billion, a PE ratio of -11.53 and a beta of 0.71. The firm has a 50 day simple moving average of $24.82 and a 200-day simple moving average of $20.67. Pacira BioSciences, Inc. has a one year low of $11.16 and a one year high of $31.67. The company has a current ratio of 2.25, a quick ratio of 1.89 and a debt-to-equity ratio of 0.51.

Pacira BioSciences Profile

Pacira Biosciences, Inc is a holding company, which engages in the provision of non-opioid pain management and regenerative health solutions to improve patients' journeys along the neural pain pathway. Its products include EXPAREL, iovera, and DepoFoam. The company was founded in December 2006 and is headquartered in Tampa, FL.